• HLA;
  • IgA nephropathy;
  • kidney transplantation;
  • recurrence

No clinical risk factors for recurrence of immunoglobulin A (IgA) nephropathy in kidney transplants have been defined. This is a single-centre retrospect analysis of recurrence in 104 first kidney transplant patients with biopsy-verified IgA nephropathy. Fifty patients had living donors. All but an identical twin were treated with cyclosporin A. The median follow-up time was 5 yr. Graft biopsies had been obtained from 35 grafts later than 6 months after transplantation, due to deteriorating graft function or gross proteinuria. Thirteen biopsies showed mesangial glomerulopathy – proliferative in eleven cases – with IgA deposits. Recurrence caused failure of six grafts. Eleven grafts with recurrence were from living donors (p=0.005). No specific human leukocyte antigen (HLA) was identified as a risk factor. Known duration of original disease until end-stage renal failure was significantly shorter in patients with recurrence (median 5 yr, range 0–25 yr) compared with those without (median of 10 yr, range of 0–37 yr) (p=0.015). Cumulative graft survival was not reduced in living versus cadaveric donor recipients.